Litonit: evaluation of clinical effectiveness.
Clinical data are presented on a new anti-alcoholic drug, litonit. A substantial reduction in the pathological addiction to alcohol takes place under the effect of litonit, and a stable aversive reaction to alcohol develops. The new drug is distinguished by its low toxicity, good tolerance, and its failure to cause disorders of the liver and kidneys even after chronic administration.
Kresyn
V I
VI
Chair of General and Clinical Pharmacology, N.I. Pirogov Medical Institute, Odessa, Ukraine.
Aryaev
V L
VL
Kostev
F I
FI
D000328:Adult; D000368:Aged; D000437:Alcoholism / Q000534:rehabilitation*; D004311:Double-Blind Method; D006801:Humans; D007668:Kidney / Q000187:drug effects; D008094:Lithium / Q000009:adverse effects; D008297:Male; D008875:Middle Aged; D009539:Nicotinic Acids / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D010919:Placebos; D013375:Substance Withdrawal Syndrome / Q000517:prevention & control
D009539:Nicotinic Acids; D010919:Placebos; C041554:litonit; D008094:Lithium